<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="229">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05158166</url>
  </required_header>
  <id_info>
    <org_study_id>21-33778</org_study_id>
    <nct_id>NCT05158166</nct_id>
  </id_info>
  <brief_title>DaxibotulinumtoxinA Injection for Treatment of Adductor Spasmodic Dysphonia</brief_title>
  <official_title>DaxibotulinumtoxinA Injection for Treatment of Adductor Spasmodic Dysphonia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Spasmodic Dysphonia (SD) is a neurologic condition causing inappropriate contraction of the&#xD;
      laryngeal musculature, leading to abnormal voicing. The three types (adductor, abductor, and&#xD;
      mixed) affect varying muscle groups which produce characteristic voice patterns. The vast&#xD;
      majority of patients with SD have adductor type, which impacts the lateral cricoarytenoid and&#xD;
      thyroarytenoid muscle complex. While many treatment modalities have been investigated, the&#xD;
      most effective treatment is botulinum toxin injection to these muscle groups, performed&#xD;
      transcervically with or without electromyography (EMG) guidance. Patients undergoing this&#xD;
      treatment typically require re-injection every 3 months. Due to its specialized nature, the&#xD;
      laryngeal injections are not performed routinely outside of academic medical centers; thus,&#xD;
      patients may come from a distance to receive this treatment. Both due to the significant&#xD;
      impact on voice quality when the injections wear off and the sometimes challenging access to&#xD;
      treatment, a longer-acting agent is desired.&#xD;
&#xD;
      Injectible daxibotuliumtoxinA (DAXI, Revance Therapeutics Inc., Newark, CA) has been shown in&#xD;
      large clinical trials to provide safe, effective treatment for glabellar lines and cervical&#xD;
      dystonia and may offer a longer-lasting result when compared with onabotulinumtoxinA.&#xD;
&#xD;
      Thus, a study examining the effect of DAXI for patients with adductor spasmodic dysphonia is&#xD;
      proposed. This study aims to assess the efficacy of DAXI for transcervical laryngeal&#xD;
      injection in patients with adductor spasmodic dysphonia.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 2022</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Our primary outcome is the difference in VHI-10 score at 6 weeks after injection with DAXI.</measure>
    <time_frame>6 weeks</time_frame>
    <description>This will be determined using a paired t-test with subjects pre-treatment VHI-10 scores as a control.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>A secondary outcome will be comparing the duration of effect of DAXI with patients' prior Botox treatment.</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Specifically, we will determine the median time to baseline VHI-10 after treatment with DAXI and produce a Kaplan-Meier curve to illustrate the duration of clinical benefit.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Adductor Spasmodic Dysphonia</condition>
  <condition>Voice Disorders</condition>
  <condition>Spasmodic Dysphonia</condition>
  <arm_group>
    <arm_group_label>Administration of Daxi</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Injectible daxibotulinumtoxinA (DAXI, Revance Therapeutics Inc., Newark, CA) is an investigational botulinum toxin type A which has been shown in large clinical trials to provide safe, effective treatment for glabellar lines and cervical dystonia and may offer longer-lasting results when compared with onabotulinumtoxinA. Dosage will be same number of units as prior Botox A dose.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DaxibotulinumtoxinA</intervention_name>
    <description>This is a long-acting alternative to traditional Botox A treatment.</description>
    <arm_group_label>Administration of Daxi</arm_group_label>
    <other_name>DAXI</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  greater than 18&#xD;
&#xD;
          -  diagnosis of adductor spasmodic dysphonia&#xD;
&#xD;
          -  previous successful treatment with BotoxA&#xD;
&#xD;
          -  stabilized dose for last 3 treatments&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  age less than 18&#xD;
&#xD;
          -  exclusively having other neurologic conditions such as:&#xD;
&#xD;
               -  abductor spasmodic dysphonia&#xD;
&#xD;
               -  ALS&#xD;
&#xD;
               -  Multiple sclerosis&#xD;
&#xD;
               -  Parkinson's disease&#xD;
&#xD;
               -  Essential tremor&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clark Rosen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCSF</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Carruthers J, Solish N, Humphrey S, Rosen N, Muhn C, Bertucci V, Swift A, Metelitsa A, Rubio RG, Waugh J, Quiring J, Shears G, Carruthers A. Injectable DaxibotulinumtoxinA for the Treatment of Glabellar Lines: A Phase 2, Randomized, Dose-Ranging, Double-Blind, Multicenter Comparison With OnabotulinumtoxinA and Placebo. Dermatol Surg. 2017 Nov;43(11):1321-1331. doi: 10.1097/DSS.0000000000001206.</citation>
    <PMID>28614091</PMID>
  </reference>
  <reference>
    <citation>Jankovic J, Truong D, Patel AT, Brashear A, Evatt M, Rubio RG, Oh CK, Snyder D, Shears G, Comella C. Injectable DaxibotulinumtoxinA in Cervical Dystonia: A Phase 2 Dose-Escalation Multicenter Study. Mov Disord Clin Pract. 2018 Apr 26;5(3):273-282. doi: 10.1002/mdc3.12613. eCollection 2018 May-Jun.</citation>
    <PMID>30009213</PMID>
  </reference>
  <reference>
    <citation>Carruthers JD, Fagien S, Joseph JH, Humphrey SD, Biesman BS, Gallagher CJ, Liu Y, Rubio RG; SAKURA 1 and SAKURA 2 Investigator Group; SAKURA 1 and SAKURA 2 Investigator Group includes the following. DaxibotulinumtoxinA for Injection for the Treatment of Glabellar Lines: Results from Each of Two Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Studies (SAKURA 1 and SAKURA 2). Plast Reconstr Surg. 2020 Jan;145(1):45-58. doi: 10.1097/PRS.0000000000006327.</citation>
    <PMID>31609882</PMID>
  </reference>
  <reference>
    <citation>Stone HF, Zhu Z, Thach TQ, Ruegg CL. Characterization of diffusion and duration of action of a new botulinum toxin type A formulation. Toxicon. 2011 Aug;58(2):159-67. doi: 10.1016/j.toxicon.2011.05.012. Epub 2011 May 31.</citation>
    <PMID>21658400</PMID>
  </reference>
  <reference>
    <citation>Rumbach A, Aiken P, Novakovic D. RETRACTED: Outcome Measurement in the Treatment of Spasmodic Dysphonia: A Systematic Review of the Literature. J Voice. 2019 Sep;33(5):810.e13-810.e39. doi: 10.1016/j.jvoice.2018.03.011. Epub 2018 Apr 11. Erratum in: J Voice. 2021 Mar;35(2):331.</citation>
    <PMID>29655932</PMID>
  </reference>
  <verification_date>December 2021</verification_date>
  <study_first_submitted>November 19, 2021</study_first_submitted>
  <study_first_submitted_qc>December 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 15, 2021</study_first_posted>
  <last_update_submitted>December 1, 2021</last_update_submitted>
  <last_update_submitted_qc>December 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adductor spasmodic dysphonia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dysphonia</mesh_term>
    <mesh_term>Hoarseness</mesh_term>
    <mesh_term>Voice Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
    <mesh_term>abobotulinumtoxinA</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

